Incretin Atlas › Trials › SYNCHRONIZE-1
SYNCHRONIZE-1
Survodutide · obesity
Design
- Molecule(s)
- Survodutide
- Population
- obesity
- Official title
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
- Sponsor
- Boehringer Ingelheim
- Phase
- 3
- Registry status
- completed · 2023-11 → 2025-12
- Participants
- 726
- Duration
- 76 weeks
- Registry
- NCT06066515
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| survodutide 3.6 mg | obesity | 76 | 241 | −15.3 % vs −3.2 % Δ −12.1 pp | −12.2 % vs −5.4 % Δ −6.8 pp | −0.2 vs +0.0 | 23.7 vs 5.4 | 35.3 vs 40.1 | 61.0 vs 17.4 | 40.7 vs 6.2 | 8.3 vs 6.2 | −6.7 vs −5.9 | verified |
| survodutide 6.0 mg | obesity | 76 | 242 | −16.6 % vs −3.2 % Δ −13.4 pp | −13.0 % vs −5.4 % Δ −7.6 pp | −0.2 vs +0.0 | 24.8 vs 5.4 | 34.3 vs 40.1 | 64.9 vs 17.4 | 44.6 vs 6.2 | 8.3 vs 6.2 | −5.4 vs −5.9 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- survodutide 3.6 mg: Any discontinuation = 100 − % still on drug at week 76.
Verbatim quotes from the source (18)
- survodutide 3.6 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
−15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
- survodutide 3.6 mg · weight_tp · Table 1
Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
- survodutide 3.6 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
- survodutide 3.6 mg · nausea · Table 3
Nausea 147 (61.0) 157 (64.9) 42 (17.4)
- survodutide 3.6 mg · vomiting · Table 3
Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
- survodutide 3.6 mg · sae · Table 3
Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
- survodutide 3.6 mg · hba1c · Table 2
Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
- survodutide 3.6 mg · sbp · Table 1
Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
- survodutide 3.6 mg · disc_any · Results, participants paragraph
63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)
- survodutide 6.0 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
−15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
- survodutide 6.0 mg · weight_tp · Table 1
Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
- survodutide 6.0 mg · ae_dc · Table 3
Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
- survodutide 6.0 mg · nausea · Table 3
Nausea 147 (61.0) 157 (64.9) 42 (17.4)
- survodutide 6.0 mg · vomiting · Table 3
Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
- survodutide 6.0 mg · sae · Table 3
Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
- survodutide 6.0 mg · hba1c · Table 2
Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
- survodutide 6.0 mg · sbp · Table 1
Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
- survodutide 6.0 mg · disc_any · Results, participants paragraph
63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)
Primary sources
- le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026;395(8):776-787. PMID: 42253238.
- ClinicalTrials.gov NCT06066515
How to cite this page
Medical Adviser's Group. Incretin Atlas: SYNCHRONIZE-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.